Atia Vision, Inc., a Shifamed portfolio company committed to improving patient outcomes through the development of a modular presbyopia-correcting accommodating intraocular lens, announced today initial closing of its committed $20M Series D preferred stock financing. Financing was led by Cormorant Asset Management, with participation by The Capital Partnership (TCP), AMED Ventures and Shangbay Capital. The financing will be used to advance Atia Vision’s clinical efforts.
“We are extremely pleased to close this latest round of financing with strong, continued support from our investors,” stated Mariam Maghribi, President and CEO of Atia Vision. “We look forward to furthering our clinical studies and demonstrating the performance of our technology, which aims to restore the full range of functional vision for patients suffering from cataracts and presbyopia.”
Nearly 67 million people worldwide are visually impaired due to cataracts, which can lead to blindness if untreated.1 Atia Vision’s innovation addresses the unmet needs of cataract and presbyopia patients through a familiar conventional cataract procedure. The Atia Vision modular intraocular lens technology features an accommodating base responsive to the ciliary muscles, simulating the natural mechanism of the eye and fixed lens element that allows for subsequent refractive correction.
“Atia Vision’s proprietary technology represents an elegant advancement that uniquely addresses clinical challenges currently facing the visual impairment space, of which cataracts and presbyopia are the largest segments,” commented Bihua Chen, Cormorant Asset Management Founder and CEO. “We are proud to further strengthen our partnership with Atia Vision and look forward to delivering this next-generation solution to the ophthalmology market.”
About Atia Vision, Inc.
Atia Vision is a privately held medical device company formed by Shifamed LLC, a Silicon Valley based medical innovation hub. To learn more about Atia Vision, please visit www.atiavision.com.